Anemia

FDA clears study of HEMOLINK as a treatment for chemotherapy-induced anemia

Published in Blood Weekly, May 2nd, 2002

Hemosol, Inc., (HMSL) announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a phase II clinical trial of its flagship product, Hemolink (hemoglobin raffimer), as a treatment for chemotherapy-induced anemia.

The single-blind, dose-comparison study will evaluate the safety and tolerability of a short course of HEMOLINK in 50 patients with lung or ovarian cancer who are being treated with erythropoietin for chemotherapy-induced anemia. The multicenter study will be led by investigators at Duke University and is expected to begin enrolling patients in June of 2002.

"The market opportunity created by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry